Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Operating Activities:    
Net loss $ (6,843) $ (748)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on warrants [note 7 and note 8 [f]] (111)  
Depreciation and amortization [note 4] 191 166
Deferred income tax (recovery) [note 2 and note 4] (3,051) (377)
Non cash (gain) loss on foreign exchange   4
Stock-based compensation [note 8 [c] and note 8 [d]] 152  
Bargain purchase gain [note 2] (1,272)  
Loss on disposition [note 4] 8,610  
Contingent value rights liability recovery [note 4] (200)  
Changes in operating assets and liabilities:    
Amounts receivable (164)  
Prepaid expenses and other assets (1,597) (3)
Accounts payable 400 48
Accrued liabilities other (1,123) 299
Accrued clinical liabilities 162  
Accrued compensation (685) 471
Lease obligation 47  
Net cash used in operating activities (5,484) (140)
Financing Activities:    
Proceeds from Loans, net of issuance costs   100
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs 1,129  
Taxes paid related to net share settlement of equity awards (22)  
Net cash provided by financing activities 1,107 100
Investing Activities:    
Cash received on reverse merger of OncoGenex [note 2] 12,376  
Net cash provided by investing activities 12,376  
Effect of exchange rate changes on cash 7  
Net increase (decrease) in cash and cash equivalents 8,006 (40)
Cash and cash equivalents at beginning of period 15 67
Cash and cash equivalents at end of period $ 8,021 $ 27